Newroom
Major breakthrough in potential new treatment for Sepsis with Sulfateq’s lead compound SUL-138
Great news! A new scientific paper has been published about the potential of a new medicine, SUL-138, to help treat sepsis. Sepsis is a serious health problem, but right now doctors can only use antibiotics and supportive care to help patients....
Sulfateq is proud to announce the results of a new study which might provide a new way to treat Alzheimer’s disease.
Alzheimer’s Disease (AD) is a complex and progressive neurodegenerative disease which is characterized by memory loss and cognitive impairment. It is one of the most prevalent neurodegenerative diseases and it is estimated that the number of...
Sulfateq is in the finals of the LIFE Science Innovation Award!
We at Sulfateq are very proud to have reached the finals out of more than twenty applications. The Innovation Award is awarded to the innovation with the most impact in the field of Life Sciences & Health. During the final on September 27, we...
Hibernation medicine for sepsis patients
Winter sleep (hibernation) offers hibernating species the possibility to survive harsh environmental conditions, such as periods of low food availability or periods of extreme low temperatures. Hibernators lower their body temperature, breathing-...
SULFATEQ and GEN sign definitive collaboration agreement to develop a therapy for Alzheimer’s Disease and additional Neurodegenerative Diseases
Groningen, The Netherlands & Ankara, Turkey - Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a publicly traded...
SUL-151 as treatment for smoke-induced COPD
Sulfateq is happy to announce that a new scientific manuscript detailing the efficacy of SUL-151 to mitigate the development of Chronic Obstructive Pulmonary Disease (COPD), was recently published in the International Journal of Molecular Sciences....